Filing Flows

Filing Flows › Companies › CareDx › Cash flow

CareDx cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$11.1M in Q3 2026 · $69.0M over twelve months

Operating cash flow$12.7M
Capital spending−$1.6M
Free cash flow+$11.1M
Cash / net income0.7×

Analysis

In Q3 2026, CareDx generated $12.7M of operating cash flow and spent $1.6M on capital projects, leaving free cash flow of $11.1M. That is $24.9M less than in Q3 2025 ($36.1M).

Over the twelve months to Sep 30, 2026, operating cash flow was $69.0M; the largest uses were acquisitions ($146M), buybacks ($24.4M), taxes on employees’ shares ($14.8M); besides operations, cash came from other investing ($255M), shares issued ($20.2M); the cash balance rose by $160M.

Operating cash flow was $12.7M against net income of $19.3M — 0.7× profit, less cash than reported earnings, worth checking against working capital. The largest differences: accrued liabilities −$11.6M, stock-based pay +$9.7M, receivables −$9.0M.

Free cash flow

CareDx: free cash flow by quarterCareDx: free cash flow by quarter$21.9MQ4 2024−$28.2MQ1 2025$8.9MQ2 2025$36.1MQ3 2025$21.4MQ4 2025$514KQ1 2026$28.7MQ2 2026$11.1MQ3 2026
Operating cash flow less capital spending.
CareDx: operating cash flow against capital spendingCareDx: operating cash flow against capital spendingOperating cash flowCapital spending$21.9M$0Q4 2024−$26.6M$1.6MQ1 2025$9.9M$1.0MQ2 2025$37.4M$1.3MQ3 2025$21.4M$0Q4 2025$4.3M$3.8MQ1 2026$30.6M$1.9MQ2 2026$12.7M$1.6MQ3 2026
Latest (Q3 2026): Operating cash flow $12.7M, Capital spending $1.6M.

Capital allocation, year by year

CareDx: where the cash came from (up) and went (down), by fiscal yearCareDx: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAcquisitionsBuybacksFY2021: Operating cash flow −$19.3MFY2021: Net borrowing −$66KFY2021: Shares issued $202MFY2021: Acquisitions −$15.4M$202MFY2021FY2022: Operating cash flow −$25.2MFY2022: Shares issued $2.4MFY2022: Acquisitions −$610KFY2022: Buybacks −$642K$2.4MFY2022FY2023: Operating cash flow −$18.4MFY2023: Shares issued $120KFY2023: Acquisitions −$6.7MFY2023: Buybacks −$27.5M$120KFY2023FY2024: Operating cash flow $38.0MFY2024: Shares issued $8.9MFY2024: Buybacks −$522K$47.0MFY2024FY2025: Operating cash flow $42.0MFY2025: Shares issued $5.7MFY2025: Buybacks −$87.8M$47.8MFY2025
Over these 5 years operating cash flow totalled $17.2M; the largest uses were buybacks ($116M) and operating cash flow ($62.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$250M
Debtnone
Net cash$250M

CareDx funds itself: free cash flow was $69.0M over the last twelve months, with $250M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

CareDx: sources (+) and uses (−) of cash, Q3 2026CareDx: sources (+) and uses (−) of cash, Q3 2026Other investing−$146MCash drawn (+) / kept (−)$122MShares issued$17.5MOperating cash flow$12.7MTaxes on employees’ shares−$4.6MCapital spending−$1.6M
CareDx: sources (+) and uses (−) of cash, TTM to Q3 2026CareDx: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$255MCash drawn (+) / kept (−)−$160MAcquisitions−$146MOperating cash flow$69.0MBuybacks−$24.4MShares issued$20.2MTaxes on employees’ shares−$14.8MOther financing$997KExchange rates$10K

From profit to cash

CareDx: net income to operating cash flow, Q3 2026CareDx: net income to operating cash flow, Q3 2026Net income$19.3MDepreciation & amortization$7.2MStock-based pay$9.7MOther non-cash$426KReceivables−$9.0MInventory−$841KPayables$1.3MAccrued liabilities−$11.6MDeferred revenue$1.4MOperating cash flow$12.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingBuybacksShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$12.7M−$1.6M—$17.5M$122M$11.1M
Q2 2026$30.6M−$1.9M—$1.2M−$296M$28.7M
Q1 2026$4.3M−$3.8M—$109K−$12.5M$514K
Q4 2025$21.4M—−$12.2M$1.4M$26.0M$21.4M
Q3 2025$37.4M−$1.3M−$25.6M$232K−$23.2M$36.1M
Q2 2025$9.9M−$1.0M−$50.0M$1.0M$20.5M$8.9M
Q1 2025−$26.6M−$1.6M—$3.0M$26.0M−$28.2M
Q4 2024$21.9M——$5.6M−$19.3M$21.9M

CareDx: income statement and cash flow

CareDx, Q3 2026: revenue $139M (+39% year over year), operating margin 5.8%. The chart follows the revenue to costs, profit and cash.

CareDx: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.